Solid Biosciences Inc. is a life sciences company focused on advancing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases. The company develops adeno associated virus based treatments that deliver functional genes to address the underlying genetic causes of conditions such as Duchenne muscular dystrophy Friedreichs ataxia catecholaminergic polymorphic ventricular tachycardia and other inherited cardiac disorders. Its pipeline includes both clinical stage and preclinical candidates targeting muscle and heart tissue.

Solid Biosciences Inc. generates revenue through upfront license fees milestone payments and royalties from collaboration and licensing agreements with academic institutions and biotechnology partners. The company also receives potential future milestone payments from outlicensing its proprietary capsid technology and may earn royalties on net sales of licensed products. Additionally research funding and grant contributions contribute to its income.

Solid Biosciences Inc. competes with established biotechnology firms such as Sarepta Therapeutics Genethon REGENXBIO and Insmed in the Duchenne muscular dystrophy space. In Friedreichs ataxia it faces competition from Lexeo Therapeutics Neurocrine Biosciences and the approved therapy Biogen's SKYCLARYS. For catecholaminergic polymorphic ventricular tachycardia competitors include Cardurion Pharmaceuticals and other early stage biotech companies. The company differentiates itself through its proprietary capsid platform its novel microdystrophin construct and its integrated research capabilities in vector design and manufacturing.

Solid Biosciences Inc. serves patients with rare neuromuscular and cardiac diseases through its clinical trial programs and collaborates with hospitals research institutions and patient advocacy groups. The company works with clinical sites across the United States Canada Europe and the United Kingdom to enroll participants in its studies. While no commercial product is currently available its customer base consists of the patient communities and healthcare providers involved in its trials.